Paul Hastings Advises ACELYRIN in Alumis Merger
Paul Hastings LLP advised ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, on its merger agreement with Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases.
The Paul Hastings team was led by global co-chair of Mergers & Acquisitions Eduardo Gallardo and partners Sean Donahue and Andrew Goodman.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.